LEXINGTON, Mass. , July 15, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that Theo Melas-Kyriazi

Members of leadership team to participate in sessions discussing the role of the microbiome in human disease Summit coincides with World Microbiome Day: June 27, 2019 LEXINGTON, Mass. , June 26, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company

LEXINGTON, Mass. , June 03, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that

LEXINGTON, Mass. , May 02, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced financial

LEXINGTON, Mass. , April 12, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc . (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today presented

Johan van Hylckama Vlieg, Ph.D., Named Chief Scientific Officer and Clare Fisher Appointed Chief Business Officer LEXINGTON, Mass. , April 08, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc . (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to

Posters to feature ex vivo and in-human data supporting Kaleido’s Microbiome Metabolic Therapy programs for the treatment of hyperammonemia LEXINGTON, Mass. , March 27, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated,

Studies are evaluating novel Microbiome Metabolic Therapies, KB195 and KB174, in target patient populations; data expected in Q4 2019 Third non-IND clinical study in healthy subjects also underway to evaluate dosing of KB174 LEXINGTON, Mass. , March 21, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences,

LEXINGTON, Mass. , March 08, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences , (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that a

LEXINGTON, Mass. , March 04, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced the